Logo

OSUR

OraSure Technologies, Inc.

OSUR

OraSure Technologies, Inc. • NASDAQ
$2.38 ▲ 0.00% (+0.00)
Market Cap $176.82 M
52w High $4.22
52w Low $2.08
Dividend Yield 0%
P/E -2.94
Volume 120.84K
Outstanding Shares 74.29M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $27.085M ▼ $27.862M ▼ $-13.712M ▲ -50.626% ▲ $-0.19 ▲ $-11.21M ▲
Q2-2025 $31.242M ▲ $31.185M ▲ $-19.693M ▼ -63.034% ▼ $-0.26 ▼ $-14.877M ▲
Q1-2025 $29.931M ▼ $30.049M ▲ $-16.04M ▼ -53.59% ▼ $-0.21 ▼ $-15.494M ▼
Q4-2024 $37.445M ▼ $25.984M ▲ $-10.794M ▼ -28.826% ▼ $-0.14 ▼ $-9.921M ▼
Q3-2024 $39.915M $23.069M $-4.507M -11.291% $-0.06 $-3.431M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $216.478M ▼ $423.098M ▼ $61.118M ▼ $361.98M ▼
Q2-2025 $234.578M ▼ $445.035M ▼ $64.314M ▲ $380.721M ▼
Q1-2025 $247.569M ▼ $457.607M ▼ $61.325M ▼ $396.282M ▼
Q4-2024 $267.763M ▼ $479.659M ▲ $69.321M ▲ $410.338M ▼
Q3-2024 $278.571M $464.085M $38.52M $425.565M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-13.712M ▲ $-10.071M ▲ $-821K ▲ $-5.079M ▲ $-18.1M ▼ $-10.99M ▲
Q2-2025 $-19.693M ▼ $-10.223M ▲ $-1.936M ▼ $-5.798M ▼ $-12.991M ▲ $-12.159M ▲
Q1-2025 $-16.04M ▼ $-19.733M ▼ $370K ▲ $-953K ▼ $-20.194M ▼ $-20.153M ▼
Q4-2024 $-10.794M ▼ $109K ▼ $-5.493M ▼ $-111K ▲ $-10.808M ▼ $-347K ▼
Q3-2024 $-4.507M $12.682M $7.332M $-727K $20.332M $12.537M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Other Revenues
Other Revenues
 $0 ▲$0 ▲$0 ▲$0 ▲
Product And Services
Product And Services
 $90.00M ▲$30.00M ▼$30.00M ▲$30.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue climbed steadily for several years and then fell sharply in the most recent year, suggesting that some earlier demand (likely pandemic- or public-health-driven testing) has faded. Profitability has been inconsistent: the company showed a clearly profitable year recently but has posted small losses in most other years. Margins are relatively thin, so swings in sales quickly translate into swings between profit and loss. The encouraging sign is that OraSure has demonstrated it can earn money at higher volumes; the challenge is stabilizing demand so those profits are repeatable rather than one-offs.

Balance Sheet

Balance Sheet The balance sheet is a key strength. Assets have grown gradually, and cash makes up a large portion of those assets. Debt is minimal, and shareholder equity is solid, indicating a conservative financial structure. Recent disclosures point to a very sizeable cash reserve and essentially no debt, which gives the company resilience during periods of weaker earnings and flexibility to fund acquisitions and product development without relying heavily on borrowing.

Cash Flow

Cash Flow Cash flow paints a more positive picture than the income statement alone. A few years ago the business was burning cash, but more recently it has generated healthy positive cash flow from operations, with free cash flow turning positive and staying that way, even as earnings dipped again. Investment spending on equipment and facilities has been modest relative to the cash generated, implying that the business is not overly capital intensive. Overall, the company appears able to fund its growth initiatives from internal cash, while its large cash balance offers an additional buffer.

Competitive Edge

Competitive Edge OraSure holds a distinctive niche in non-invasive diagnostics, especially oral-fluid testing and easy-to-use sample collection. The OraQuick brand is well known in areas like HIV testing and benefits from first-mover status and regulatory approvals that are not easy for rivals to replicate. Its DNA Genotek unit strengthens its position in genomics and microbiome sample collection. The company’s moat is built on specialized know-how, patents, regulatory expertise, and established relationships with public health organizations and research customers. However, it still operates in a competitive market with larger diagnostic players, and its past revenue volatility suggests exposure to shifting public-health priorities and funding cycles.

Innovation and R&D

Innovation and R&D Innovation is a clear focal point. OraSure has expanded beyond legacy rapid tests into more advanced molecular diagnostics, especially with the acquisition of Sherlock Biosciences. That deal brings in cutting-edge testing platforms designed for quick, accurate, at-home use. The planned at-home test for key sexually transmitted infections, plus partnerships for additional STI and respiratory tests, point to a pipeline that could materially broaden the product mix over the next few years. New sample collection devices for urine and blood also extend the company’s reach into more types of at-home and research testing. The main risks are execution and regulatory timing: turning this promising pipeline into cleared, widely adopted products will take time, investment, and successful navigation of regulators.

Summary

OraSure looks like a company in transition. Historically, it benefited from spikes in testing demand but did not maintain steady, strong profitability, as seen in the recent step down in revenue after a peak year. At the same time, it has built and preserved a strong financial foundation, with substantial cash and almost no debt, and has a distinctive position in non-invasive, at-home, and point-of-care diagnostics. Management appears to be using that financial strength to push deeper into molecular and at-home testing through acquisitions and partnerships, aiming to create a more diversified, sustainable growth engine. Key things to watch going forward are whether the company can smooth out its revenue swings, keep margins healthy as it scales new products, and convert its innovative pipeline into durable, recurring business rather than one-time surges in demand.

NEWS

October 29, 2025 · 7:30 AM UTC

OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th

Read more

October 28, 2025 · 4:22 PM UTC

OraSure Technologies Appoints Steven K. Boyd to its Board of Directors

Read more